MBX Biosciences director granted stock options
MBX Biosciences director Steven L. Hoerter received a stock option grant as part of his non-employee director compensation.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
MBX Biosciences director Steven L. Hoerter received a stock option grant as part of his non-employee director compensation. The options have an exercise price of $27.08 per share and expire on November 21, 2035. The grant vests in equal monthly installments over one year from November 6, 2025, and was adjusted so his 2025 equity compensation does not exceed $1,000,000 in aggregate grant date fair value under the company’s director compensation policy.
Insider Trade Summary
Grant/Award: 0 shares
Grant/Award
1 txn
Insider
Hoerter Steven L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 0 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 0 contracts (Direct)
Footnotes (2)
- F1. Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
- F2. The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company.
Key Figures
Option exercise price: $27.08 per share
Expiration date: November 21, 2035
Equity compensation cap: $1,000,000
+1 more
4 metrics
Option exercise price
$27.08 per share
Exercise price of director stock option grant
Expiration date
November 21, 2035
Option expiration for director grant
Equity compensation cap
$1,000,000
Maximum 2025 annual equity compensation based on grant date fair value
Vesting schedule length
One year
Equal monthly vesting from November 6, 2025
Key Terms
Non-Employee Director Compensation Policy, grant date fair value, FASB Topic ASC 718, vest in equal monthly installments
4 terms
Non-Employee Director Compensation Policy financial
"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward..."
grant date fair value financial
"annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value..."
The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.
FASB Topic ASC 718 financial
"aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."
vest in equal monthly installments financial
"The grant will vest in equal monthly installments over a one-year period..."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did MBX director Steven L. Hoerter report on Form 4/A for MBX?
Steven L. Hoerter reported receiving a stock option grant as non-employee director compensation. The options carry a $27.08 exercise price and expire November 21, 2035, with vesting in equal monthly installments over one year starting November 6, 2025.
What is the exercise price and expiration date of Steven Hoerter’s new MBX stock options?
The granted stock options have a $27.08 per share exercise price and an expiration date of November 21, 2035. These terms define the cost to purchase MBX common stock and the final date the options can be exercised if vested and outstanding.
How do Steven Hoerter’s MBX director options vest under this Form 4/A filing?
The grant will vest in equal monthly installments over a one-year period starting November 6, 2025. Vesting is conditioned on Mr. Hoerter’s continued service as a non-employee director, aligning his equity compensation with ongoing board participation during that year.
How does MBX’s Non-Employee Director Compensation Policy affect Hoerter’s 2025 equity awards?
Under MBX’s Non-Employee Director Compensation Policy, Hoerter’s grants were adjusted so his 2025 annual equity compensation totals no more than $1,000,000. This limit is based on aggregate grant date fair value calculated in accordance with FASB Topic ASC 718 accounting standards.
Is Steven Hoerter’s MBX Form 4/A transaction a market purchase or sale of common stock?
No, the Form 4/A reflects a grant of stock options as compensation, not a market purchase or sale of common shares. It records a derivative award with a $27.08 exercise price, vesting monthly over one year, subject to his continued service as a non-employee director.
AI-generated analysis. How Rhea-AI works. Not financial advice.
